{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"peripheral-neuropathy","urls":{"read":"https://miscsubjects.com/api/articles/peripheral-neuropathy/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/peripheral-neuropathy/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/peripheral-neuropathy/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/peripheral-neuropathy/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/peripheral-neuropathy/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/peripheral-neuropathy/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/peripheral-neuropathy/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"peripheral-neuropathy","title":"Peripheral neuropathy: the longest nerves fail first, so it starts in both feet","register":"accessible","tags":[],"updated_at":"2026-08-05T09:18:31.962Z","body_excerpt":"It starts in the toes because they are furthest away. The nerves running to your feet are the longest cells in your body — a single one can run from the base of your spine to your big toe — and anything that starves or poisons a nerve hits the far end first, where the supply line is longest. That is why this begins in both feet at once rather than in one leg, why it creeps upward over months and years rather than jumping about, and why the hands only join in later, when the damage has climbed the legs to roughly the height of the knee.\n\nThat pattern is worth memorising, because it is what separates this from a pinched nerve. A pinched nerve in the back gives you one leg, in a stripe. This gives you both feet, evenly, in the shape of a sock.\n\n## The first job is not treating the pain. It is finding a cause you can reverse.\n\nMost of what gets written about neuropathy is about pain medication. That skips the step that matters more, because some causes of this are correctable and the nerves recover if you correct them early enough.\n\nThe one most often missed is vitamin B12, and the reason it is missed is that a common diabetes drug causes it. Metformin interferes with B12 absorption over years. A 2026 case report describes exactly what that looks like when nobody checks: nerve and spinal cord damage in someone on long-term metformin, which improved substantially over the following weeks once treated.\n\n[[embed:source:s1]]\n\nIf you have been on metformin for years and have numb feet, the assumption that your neuropathy is diabetic is a coin flip, not a diagnosis. A B12 level is a cheap blood test and the treatment is injections.\n\nThe other reversible or modifiable causes worth ruling out before settling for pain control: alcohol intake, thyroid function, kidney function, and chemotherapy exposure.\n\n## Even long-standing nerve damage is not necessarily one-way\n\nThe standard belief — patient and clinician alike — is that once the nerves are damaged, the direction is downward and treatment is about slowing it. A 2026 study followed people with type 1 diabetes over five years and found something more useful than that.\n\nYes, overall prevalence rose over the five years. But individual people moved in both directions: some regressed to less severe disease, and some no longer met the criteria at all.\n\n[[embed:source:s2]]\n\nThe authors' conclusion is the sentence to carry: continued intervention remains worthwhile well after the diagnosis has been made. Someone told years ago that they have neuropathy, who concluded that glucose control no longer mattered for their feet, was told something the data does not support.\n\n## Screening exists, it is cheap, and it is often not done\n\nThere is an agreed way to detect this before it becomes a foot problem, and it requires two instruments that cost almost nothing.\n\n[[embed:source:s3]]\n\nA monofilament — a nylon thread pressed against the sole until it buckles — and a tuning fork. Annually. If you have diabetes and cannot remember the last time somebody touched your feet with either, that is a reasonable thing to ask for by name.\n\nThe reason to insist is in the numbers on what happens when nobody checks. In a 2026 study of people over 60 with diabetes, peripheral neuropathy raised the odds of being in the at-risk foot category by roughly ninefold.\n\n[[embed:source:s4]]\n\nNinefold. Not the pain — the foot. Numbness means injuries do not announce themselves, and the sequence that ends in amputation usually starts with something the person never felt.\n\n## What the drugs actually do, and which one first\n\nBe clear about what these are for: they reduce pain. None of them repairs a nerve. A 2026 review states the position plainly — treatment of the underlying nerve damage remains limited, and studies of causal therapy have produced conflicting results, so most treatment is glucose control plus symptom management.\n\n[[embed:source:s5]]\n\nWithin symptom management, there is a real head-to-head answer. A trial comparing","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"The first task in peripheral neuropathy is finding a reversible cause, not treating the pain.","tier":"expert","interaction_risk":false,"status":"active","source_ids":["s3","s5"],"source_status":"sourced","why_material":"Pain management on top of an untreated reversible cause allows the nerve damage to continue. The order of operations is the most consequential thing on the page.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"c2","text":"Metformin can cause functional vitamin B12 deficiency presenting as neuropathy, which is reversible once identified.","tier":"case","interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"A very common drug producing a reversible neuropathy that looks exactly like the irreversible kind. Missing it means treating nerve damage that did not have to be permanent.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"c3","text":"The course of diabetic polyneuropathy is heterogeneous rather than uniformly progressive, so long-standing nerve damage is not necessarily one-way.","tier":"observational","interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"People are routinely told the damage is permanent, which removes their reason to act. The cohort data does not support that as a blanket statement.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"c4","text":"Screening for at-risk diabetic foot disease is cheap and available and is often not performed.","tier":"observational","interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"It is the specific, actionable gap: the test that prevents the worst outcome exists, costs almost nothing, and has to be asked for.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"c5","text":"First-line drugs for neuropathic pain have been compared head to head, including pregabalin against gabapentin in meta-analysis.","tier":"rct","interaction_risk":false,"status":"active","source_ids":["s6","s7"],"source_status":"sourced","why_material":"Which drug to try first is a real comparison with real evidence, not a matter of prescriber habit.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42035456/","title":"Metformin-Associated Functional Vitamin B12 Deficiency Presenting as Subacute Combined Degeneration in a 57-Year-Old Man With Diabetes Mellitus","quote":"CONCLUSIONS This case of metformin-associated cobalamin deficiency with subacute combined degeneration of the spinal cord highlights the importance of monitoring vitamin B12 status and neurological sy","summary":"American Journal of Case Reports 2026: nerve and spinal cord damage from B12 deficiency caused by long-term metformin, which improved substantially within weeks of treatment. The commonest missed reversible cause in people who already have a diabetes label.","claim_ids":[],"hash":"09d9d89b36f25d0a23b4b4bf379e607925240122d1562218a2b517205ca498e5"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42043615/","title":"Heterogeneous course of diabetic polyneuropathy in type 1 diabetes over 5 years: is regression possible?","quote":"CONCLUSIONS: Over 5 years the overall prevalence of DPN increased; however, regression to less severe DPN or complete absence of DPN occurred.","summary":"Endocrine 2026: five years of follow-up in type 1 diabetes. Prevalence rose across the group while individuals moved both ways — some to less severe disease, some out of the diagnosis entirely. The authors conclude continued intervention remains worthwhile well after diagnosis.","claim_ids":[],"hash":"e8442138d5b22942839d89ec1f45729f2cfb331d862835a6740f42b77d4cdfb6"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41364419/","title":"Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives","quote":"Every diabetes clinic should perform annual screening for DPN to identify the risk of diabetic foot disease using a monofilament and tuning fork (or biothesiometer).","summary":"Drugs & Aging 2026: the agreed screening method, requiring two instruments that cost almost nothing, done once a year.","claim_ids":[],"hash":"ec8d701cceaf0e41835fb9e142ef47221b5781ee2383f4ba0821cb25243a9bd8"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42063783/","title":"Risk factors for diabetic at-risk foot disease among the diabetes over 60 years old: a cross-sectional study","quote":"Notably, peripheral neuropathy (PN) significantly increased the probability of at-risk foot condition by approximately 882.9% (OR = 9.829, 95% CI: 4.607-20.969, p ConclusionA high percentage of people","summary":"Frontiers in Medicine 2026: in people over 60 with diabetes, neuropathy raised the odds of an at-risk foot roughly ninefold. Numbness means an injury does not announce itself.","claim_ids":[],"hash":"d8bdae4fbe43c52bd9298579b8c19da4ecac68dd8b8667758c89b43264e65b1c"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41364419/","title":"Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives","quote":"The treatment of diabetic neuropathy remains limited, as studies on causal therapy have shown conflicting results.","summary":"The same review on what the drugs are for: treatment of the underlying nerve damage remains limited, so most of it is glucose control plus symptom management.","claim_ids":[],"hash":"59e5071c098897d89b6e144673de4d5cd65add139925cc4f85892bc69a88b69e"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39544662/","title":"Evaluation of Effectiveness and Safety of Firstline Drugs Used in the Treatment of Peripheral Neuropathy Among Elderly Population-A Randomised, Open-label, Active Comparator Study","quote":"Pregabalin was superior to amitriptyline and duloxetine, whereas it was comparable to gabapentin in effectiveness.","summary":"Annals of Neurosciences 2026: a head-to-head of the first-line drugs. The same trial counted 14 adverse events in total, the largest share of them in the duloxetine arm.","claim_ids":[],"hash":"e1a7633c36d52a610cc18dcbf4a6f313cb6b58caa15e6bcc586074c617c14c81"},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39839199/","title":"Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety","quote":"In conclusion, pregabalin demonstrated superior and faster efficacy in alleviating neuropathic pain than gabapentin did.","summary":"Frontiers in Pain Research 2024: pooled analysis separating the two drugs that came out on top — pregabalin worked better and sooner, with lower opioid use and fewer adverse events.","claim_ids":[],"hash":"4c66a419a7df719c3bdb943b4b4133ccdc9d3dc86ce615ea235355d830f90160"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42035456/","title":"Metformin-Associated Functional Vitamin B12 Deficiency Presenting as Subacute Combined Degeneration in a 57-Year-Old Man With Diabetes Mellitus","quote":"CONCLUSIONS This case of metformin-associated cobalamin deficiency with subacute combined degeneration of the spinal cord highlights the importance of monitoring vitamin B12 status and neurological sy","summary":"American Journal of Case Reports 2026: nerve and spinal cord damage from B12 deficiency caused by long-term metformin, which improved substantially within weeks of treatment. The commonest missed reversible cause in people who already have a diabetes label.","claim_ids":[],"hash":"09d9d89b36f25d0a23b4b4bf379e607925240122d1562218a2b517205ca498e5"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42043615/","title":"Heterogeneous course of diabetic polyneuropathy in type 1 diabetes over 5 years: is regression possible?","quote":"CONCLUSIONS: Over 5 years the overall prevalence of DPN increased; however, regression to less severe DPN or complete absence of DPN occurred.","summary":"Endocrine 2026: five years of follow-up in type 1 diabetes. Prevalence rose across the group while individuals moved both ways — some to less severe disease, some out of the diagnosis entirely. The authors conclude continued intervention remains worthwhile well after diagnosis.","claim_ids":[],"hash":"e8442138d5b22942839d89ec1f45729f2cfb331d862835a6740f42b77d4cdfb6"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41364419/","title":"Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives","quote":"Every diabetes clinic should perform annual screening for DPN to identify the risk of diabetic foot disease using a monofilament and tuning fork (or biothesiometer).","summary":"Drugs & Aging 2026: the agreed screening method, requiring two instruments that cost almost nothing, done once a year.","claim_ids":[],"hash":"ec8d701cceaf0e41835fb9e142ef47221b5781ee2383f4ba0821cb25243a9bd8"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42063783/","title":"Risk factors for diabetic at-risk foot disease among the diabetes over 60 years old: a cross-sectional study","quote":"Notably, peripheral neuropathy (PN) significantly increased the probability of at-risk foot condition by approximately 882.9% (OR = 9.829, 95% CI: 4.607-20.969, p ConclusionA high percentage of people","summary":"Frontiers in Medicine 2026: in people over 60 with diabetes, neuropathy raised the odds of an at-risk foot roughly ninefold. Numbness means an injury does not announce itself.","claim_ids":[],"hash":"d8bdae4fbe43c52bd9298579b8c19da4ecac68dd8b8667758c89b43264e65b1c"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41364419/","title":"Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives","quote":"The treatment of diabetic neuropathy remains limited, as studies on causal therapy have shown conflicting results.","summary":"The same review on what the drugs are for: treatment of the underlying nerve damage remains limited, so most of it is glucose control plus symptom management.","claim_ids":[],"hash":"59e5071c098897d89b6e144673de4d5cd65add139925cc4f85892bc69a88b69e"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39544662/","title":"Evaluation of Effectiveness and Safety of Firstline Drugs Used in the Treatment of Peripheral Neuropathy Among Elderly Population-A Randomised, Open-label, Active Comparator Study","quote":"Pregabalin was superior to amitriptyline and duloxetine, whereas it was comparable to gabapentin in effectiveness.","summary":"Annals of Neurosciences 2026: a head-to-head of the first-line drugs. The same trial counted 14 adverse events in total, the largest share of them in the duloxetine arm.","claim_ids":[],"hash":"e1a7633c36d52a610cc18dcbf4a6f313cb6b58caa15e6bcc586074c617c14c81"},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39839199/","title":"Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety","quote":"In conclusion, pregabalin demonstrated superior and faster efficacy in alleviating neuropathic pain than gabapentin did.","summary":"Frontiers in Pain Research 2024: pooled analysis separating the two drugs that came out on top — pregabalin worked better and sooner, with lower opioid use and fewer adverse events.","claim_ids":[],"hash":"4c66a419a7df719c3bdb943b4b4133ccdc9d3dc86ce615ea235355d830f90160"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"peripheral-neuropathy","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":5,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":5,"claims_total":5,"sources":7,"anecdotal":0,"scientific":7,"user_reports":0,"questions":0,"evidence_ingests":0}}